Abbott has announced a new collaboration with Bigfoot Biomedical that will aim to develop innovative solutions for diabetes management.

The alliance will see the companies develop and commercialise new diabetes management systems, combining Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the US market.

“Abbott is allying with Bigfoot Biomedical to develop and commercialise new diabetes management systems.“

Bigfoot will utilise Abbott's technology to create the first ever personalised, user-friendly systems intended to optimise insulin delivery without the need for fingerstick calibration of a glucose sensor.

Multiple systems will be developed using the FreeStyle Libre sensor technology, including systems designed to perform auto-titration for Bigfoot's connected insulin injection devices, as well as automated insulin delivery using Bigfoot's insulin infusion platform.

Jared Watkin, senior vice-president for diabetes care at Abbott, said: "Together with Bigfoot, we are challenging conventional methods of diabetes management by bringing together our expertise in superior glucose monitoring technology with a best-in-class insulin delivery system that is designed with the patient in mind."

FreeStyle Libre system was launched in Europe in 2014 and is now available in more than 35 countries, with over 300,000 people using the technology to manage their diabetes.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.